STERIS plc $STE Shares Acquired by Cwm LLC

Cwm LLC boosted its position in STERIS plc (NYSE:STE) by 434.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,622 shares of the medical equipment provider’s stock after purchasing an additional 26,516 shares during the period. Cwm LLC’s holdings in STERIS were worth $8,072,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Spurstone Advisory Services LLC acquired a new stake in shares of STERIS in the second quarter valued at $29,000. Geneos Wealth Management Inc. raised its position in STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 104 shares in the last quarter. Loomis Sayles & Co. L P acquired a new stake in STERIS in the 2nd quarter valued at about $54,000. Generali Investments Management Co LLC bought a new position in shares of STERIS during the 2nd quarter valued at about $56,000. Finally, CYBER HORNET ETFs LLC acquired a new position in shares of STERIS in the 2nd quarter worth approximately $62,000. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

STE has been the subject of several recent research reports. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, STERIS currently has a consensus rating of “Moderate Buy” and an average price target of $273.50.

STERIS Stock Up 0.3%

STE stock opened at $256.10 on Tuesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.37 and a quick ratio of 1.63. The firm has a market capitalization of $25.14 billion, a P/E ratio of 36.80 and a beta of 1.01. STERIS plc has a 52-week low of $200.98 and a 52-week high of $268.60. The company’s 50 day simple moving average is $254.56 and its 200-day simple moving average is $244.71.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same period in the previous year, the company posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, equities research analysts anticipate that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th were issued a dividend of $0.63 per share. The ex-dividend date was Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. STERIS’s payout ratio is currently 36.21%.

Insiders Place Their Bets

In related news, CEO Daniel A. Carestio sold 159 shares of the stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $241.82, for a total value of $38,449.38. Following the completion of the sale, the chief executive officer directly owned 51,096 shares of the company’s stock, valued at approximately $12,356,034.72. This represents a 0.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP John Adam Zangerle sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total value of $3,977,100.00. Following the sale, the vice president owned 33,669 shares of the company’s stock, valued at $8,926,998.66. The trade was a 30.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 25,203 shares of company stock valued at $6,624,667 over the last ninety days. Corporate insiders own 1.07% of the company’s stock.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.